DexCom (NASDAQ:DXCM) beats Q3 2026 sales expectations
DexCom reported Q3 2026 revenue of $1.34 billion, exceeding estimates by 1.2% and growing 11.2% year-on-year. Adjusted EPS was $0.73, beating estimates by 8.3%. Adjusted EBITDA was $435.2 million, a 2.6% beat. The company raised its full-year revenue guidance to $5.23 billion. Operating margin improved to 24.3% from 20.1% year-on-year, with organic revenue up 11%.
How this was made
The 30-second read
Why it matters
For traders, the key decision points are the beat versus consensus and the guidance midpoint lift, which can shift near-term estimate expectations and positioning.
Market read
A beat across revenue, adjusted EPS, and adjusted EBITDA with a modest guidance raise increases the probability of upward estimate revisions.
What to watch
Organic revenue growth and operating margin improvement are supportive, but the article does not disclose demand drivers, inventory dynamics, or competitive pricing, which could temper follow-through.
Background
The piece summarizes DexCom’s Q3 2026 results versus S&P analysts’ consensus and notes a slight full-year revenue guidance increase.
Ticker impact
DexCom reported Q3 2026 revenue of $1.34B vs $1.33B consensus, and lifted full-year revenue guidance to $5.23B at the midpoint.
Likely upward pressure as the market digests the guidance midpoint lift and margin improvement.
The article provides the company’s own quarterly results and an explicit guidance increase, which are direct drivers for near-term estimates and sentiment.
Market effects
Supports the broader wearable/medical device demand narrative by showing margin expansion and steady growth.
Limited, primarily US-focused read-through to medtech equities.
Low; the disclosed drivers are company-specific rather than a global macro shock.
Counterpoint
The guidance lift is small (midpoint $5.23B vs $5.22B), so upside may be capped if investors expected a larger raise.
Key entities
- companyDexCom
Reported Q3 2026 revenue, adjusted EPS, adjusted EBITDA, and slightly lifted full-year revenue guidance.
